IBB News and Press, iShares Biotechnology ETF From 01/09/23

Summary Scynexis has performed terribly during 2022 due to continued disappointment in earnings and sales ramp. New labels, including black-boxed warnings, could further hamper the slow commercial adoption of VVC indication, especially in the retail setting. We do not believe rVVC w...

Summary 2023 should be a year of progress on kidney disease, with multiple catalysts lined up from multiple companies. Chinook Therapeutics, Inc. has the best risk-reward based on: i) valuation; ii) diversity of pipeline (ERA and anti-APRIL); and iii) clear catalyst in Q3 2023 (phase 3 ...

Summary The world and economy were complex and volatile throughout 2022. In Green Alpha’s signature investing style, we helped our clients gain market exposure to the Next Economy. Investing in what’s next means valuing innovation and extrapolating the world economy as it ...

Summary OPKO Health Inc. shares get a strong sell rating from us for its own failing financial health and collapsing price. The company benefited from COVID-19 with strong revenue in 2020 and 2021 for its BioReference testing segment but it did not last. The optimism of its octogena...

Summary Thanks to its leading positions in various therapeutic areas, Merck's revenue was $14,959 million in Q3 2022, an increase of 13.7% compared to the previous year. In September 2022, Japan MHLW approved the expansion of the use of Keytruda for the treatment of various types of can...

Summary The top two mega themes in terms of global net inflows in 2022 were Climate Change-related themes and Big Data. The largest net outflows came from tech-heavy themes, led by Robotics & Automation. 2023 may bring a return to more normal markets driven by economics rather t...

IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will be added to the NAS...

Summary Biotech stocks notched multi-month highs earlier in December but then fell back in a possible bearish false breakout. Shares of one of the fund's biggest holdings is stuck in a consolidation after a big move lower earlier in 2022. With an impairment charge in the rearview mi...

Summary Global business conditions worsened in the penultimate month of the year according to the JPMorgan Global Composite PMI, compiled by S&P Global. New order expansions were seen in merely three of the 21 sectors tracked by the global PMI - software & services, pharmaceutic...

Summary Expectations surrounding central bank policy, China’s gradual reopening and a lower US dollar are key to investor sentiment in the final stretch of 2022. Central banks have increased interest rates at the fastest rate on record, and there are signs that higher yields are ...